Parametric Portfolio Associates’s Day One Biopharmaceuticals DAWN Stock Holding History

Parametric Portfolio Associates’s Portfolio DAWN Stock Details DAWN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	$149K	Buy	+15,016	New	+$198K	﹤0.01%	3499

Other funds holding DAWN

CPX

Canaan Partners XI Menlo Park, California $127M AUM 217.49% 1-Year Est. Return

AVLSA

Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Parametric Portfolio Associates's DAWN Position: Q1 2022 in Review

Parametric Portfolio Associates opened a new position in Day One Biopharmaceuticals (DAWN) in Q1 2022: 15,016 shares worth $149K. The stake represents ﹤0.01% of the portfolio and ranks #3499 among its holdings.

66 funds tracked by Wall St. Rank hold DAWN as of Q1 2022.

Parametric Portfolio Associates held 15,016 shares of Day One Biopharmaceuticals worth $149K as of Q1 2022.
Day One Biopharmaceuticals was a new Parametric Portfolio Associates position in Q1 2022.
Day One Biopharmaceuticals made up ﹤0.01% of Parametric Portfolio Associates's portfolio in Q1 2022, its #3499 holding.
66 funds tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q1 2022.

Based on Parametric Portfolio Associates's 13F filing for Q1 2022, filed 16 May 2022.